Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS
Dual endothelin-1 (ET-1) and angiotensin II (AngII) receptor antagonism with sparsentan has strong antiproteinuric actions via multiple potential mechanisms that are more pronounced, or additive, compared with current standard of care using angiotensin receptor blockers (ARBs). Considering the many...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society for Clinical investigation
2024-10-01
|
| Saila: | JCI Insight |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1172/jci.insight.177775 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|